NDLI: Interactions between oral antineoplastic agents and concomitant medication: a systematic review.

Please wait, while we are loading the content...

Year: 2017 Volume: 16

Year: 2016 Volume: 15

Year: 2015 Volume: 14

Year: 2014 Volume: 13

Year: 2013 Volume: 12

Year: 2013 Volume: 12 Issue: 6

Year: 2013 Volume: 12 Issue: 5

Year: 2013 Volume: 12 Issue: 4

Year: 2013 Volume: 12 Issue: 3

Sertindole: dilemmas for its use in clinical practice.

Lenalidomide and thalidomide in the treatment of chronic pain.

Clinical and causality assessment in herbal hepatotoxicity.

Statin use and the risk of esophageal cancer: a population-based case-control study.

Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.

The controversy of a wider statin utilization: why?

Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis.

Testosterone exposure in childhood: discerning pathology from physiology.

Oxycodone combined with opioid receptor antagonists: efficacy and safety.

Drug safety evaluation of desogestrel.

Safety evaluation of desloratadine in allergic rhinitis.

Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.

Interactions between oral antineoplastic agents and concomitant medication: a systematic review.

Year: 2013 Volume: 12 Issue: 2

Year: 2013 Volume: 12 Issue: 1

Year: 2012 Volume: 11

Year: 2011 Volume: 10

Year: 2010 Volume: 9

Year: 2009 Volume: 8

Year: 2008 Volume: 7

Interactions between oral antineoplastic agents and concomitant medication: a systematic review.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Carcelero, Esther Anglada, Helena Tuset, Montse Creus, Natalia
Description	Country affiliation: Spain Author Affiliation: Carcelero E ( Hospital Clínic Barcelona, Department of Pharmacy, Pharmacy Service, Villarroel, 170, 08036 Barcelona, Spain. ecarcele@clinic.ub.es)
Abstract	INTRODUCTION: In recent years, the number of oral antitumoral agents has considerably increased. Oral administration increases the risk of interactions, because most oral anticancer drugs are taken on a daily basis. Interactions can increase exposure to antitumoral agents or cause treatment failure. Many antitumoral drugs undergo enzymatic metabolism by cytochrome P450. As some act as inducers or inhibitors of one or more isoenzymes, they can lead to decreases or increases in plasma concentrations of concomitant drugs. Hence, cytostatic drugs can act not only as victims but also as perpetrators. P-glycoprotein, an efflux transporter, can also be involved in pharmacokinetic interactions. AREAS COVERED: A Medline search was performed to summarize the available evidence of the most clinically relevant interactions between oral chemotherapy agents and other drugs. The search covered the period from 1966 until August 2012 for each antitumoral drug using the medical subject headings 'Drug Interactions' OR 'Pharmacokinetics'. While the present review is not exhaustive, it aims to increase clinicians' awareness of potential drug-drug interactions. EXPERT OPINION: As cancer patients are often polymedicated and treated by different physicians, the risk of drug interactions between antitumoral agents and other medications is high. More clinical interaction studies are encouraged to ensure appropriate antineoplastic pharmacokinetics in clinical practice.
File Format	HTM / HTML
ISSN	14740338
Issue Number	3
Volume Number	12
e-ISSN	1744764X
Journal	Expert Opinion on Drug Safety
Language	English
Publisher	Taylor & Francis
Publisher Date	2013-05-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Antineoplastic Agents Adverse Effects Therapeutic Use Administration, Oral Cytochrome P-450 Enzyme System Metabolism Drug Interactions Humans Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in